Covishield-maker Serum Institute applies to begin trials of its second COVID-19 vaccine Covovax

By: |
Updated: Jan 30, 2021 9:47 PM

Covishield-maker Serum Institute to begin trial of second Covid-19 vaccine Covovax: In a tweet, Adar Poonawalla said, "Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!"

Covishield-maker Serum Institute applies to begin trials of its second COVID-19 vaccine CovovaxCovishield-maker Serum Institute applies to begin trials of its second COVID-19 vaccine Covovax: The announcement comes a day after Novovax Inc said that its Covid-19 vaccine Covovax was 89.3% effective in preventing Covid-19 in a trial conducting in the United Kingdom.(Representational image; Reuters/File Photo)

Serum Institute to begin trial of second Covid-19 vaccine: Makers of Covishield vaccine Serum Institute of India (SII) informed on Sunday that the Pune-based firm has applied to begin trials for another Covid-19 vaccine – Covovax. SII’s CEO Adar Poonawalla informed in a tweet that Serum Institute has applied to start the trials of another COVID-19 vaccine which it hopes to launch by June 2021.

In a tweet, Poonawalla said, “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!”

SII will be producing Covovax in partnership with Novovax Inc. The announcement comes a day after Novovax Inc said that its Covid-19 vaccine Covovax was 89.3% effective in preventing Covid-19 in a trial conducting in the United Kingdom. Novovax also stated that in the preliminary analysis Covovax proved to be effective in providing protection against the highly-contagious UK-variant of Coronavirus.

Also Read | Novavax vaccine seems effective against COVID-19, says British study

Serum’s Covishield vaccine, which was jointly developed by the University of Oxford and British-Swedish company AstraZeneca, was among the first Coronavirus vaccines in the world to gain approvals for mass inoculation.

Among other countries, India too has procured over 1 crore doses of Covishield vaccine for what is the world’s largest inoculation drive.

Prime Minister Narendra Modi launched India’s COVID-19 vaccination drive on January 16 and declared that nearly three crore healthcare and frontline workers would get the Coronavirus vaccine on priority.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1India’s COVID-19 battle: Why is there an outcry for Remdesivir and concerns over the effectiveness of vaccines on the virus
2Political war of words over COVID crisis, supply of medical oxygen to worst affected Maharashtra
3Covid-19 surge: Maharashtra reports over 67,000 new coronavirus cases, highest so far